PPARGC1A and neoplasm: Following a 72-h co-cultivation of PGC1α-overexpressing HCT116 cells with CD8+ T cells, a marked enhancement in the anti-tumor capacity of CD8+ T cells and heightened immunotherapy sensitivity of CRC cells were observed.